Petros Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Petros Pharmaceuticals, Inc. (PTPI) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$900 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$1.70K.
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$1.00K.
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $329.34K.
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was -$10.63M.
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$10.31M.
- Petros Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$13.97M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$900.00 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | -$1.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$2.70K derived: sum of 2 quarters · filed 2026-04-15 | $326.64K derived: sum of 3 quarters · filed 2026-04-15 | -$10.31M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $328.34K derived: sum of 2 quarters · filed 2025-11-13 | -$10.30M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $329.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$10.30M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$10.63M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$13.97M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$11.74M 10-Q · filed 2023-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |